Abstract
HDAC inhibition is emerging as a new strategy for cancer therapy. We previously reported that Nhydroxy- 3-{4-[2-(2-methyl-1H-indol-3-yl)-ethylsulfamoyl]-phenyl}-acrylamide (9) demonstrated potent histone deacetylases (HDAC) inhibition and anti-inflammatory effects. This continuous study provides detailed structureactivity relationship (SAR) of novel indol-3-ethylsulfamoylphenylacrylamides as anti-cancer agents. These compounds are endowed with potent HDAC inhibitory activity, almost 2.5 folds to 42 folds better than suberanilohydroxamic acid (SAHA). Compounds 8, 10, 11 and 17 exhibited significant inhibitory effects on various cancer cell lines with GI50 values in the range of 0.02 to 0.35 μM which are 10-50 folds better than SAHA. In-vivo nude mice model indicated the anti-angiogenic potential of these acrylamides. This study has indicated the potential of 3-{4-[2-(1-Ethyl-2-methyl-1H-indol-3-yl)-ethyl-N-tert-butoxycarbonylsulfamoyl]-phenyl}-N-hydroxy-acrylamide (11, mean GI50 = 0.04 μM) as a lead molecule for further development as anti-cancer agent.
Keywords: Histone, HDAC, cancer, angiogenesis, SAHA, indole, sulfonamide.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Indole-3-ethylsulfamoylphenylacrylamides with Potent Anti-proliferative and Anti-angiogenic Activities
Volume: 16 Issue: 7
Author(s): Samir Mehndiratta, Shiow-Lin Pan, Sunil Kumar and Jing-Ping Liou
Affiliation:
Keywords: Histone, HDAC, cancer, angiogenesis, SAHA, indole, sulfonamide.
Abstract: HDAC inhibition is emerging as a new strategy for cancer therapy. We previously reported that Nhydroxy- 3-{4-[2-(2-methyl-1H-indol-3-yl)-ethylsulfamoyl]-phenyl}-acrylamide (9) demonstrated potent histone deacetylases (HDAC) inhibition and anti-inflammatory effects. This continuous study provides detailed structureactivity relationship (SAR) of novel indol-3-ethylsulfamoylphenylacrylamides as anti-cancer agents. These compounds are endowed with potent HDAC inhibitory activity, almost 2.5 folds to 42 folds better than suberanilohydroxamic acid (SAHA). Compounds 8, 10, 11 and 17 exhibited significant inhibitory effects on various cancer cell lines with GI50 values in the range of 0.02 to 0.35 μM which are 10-50 folds better than SAHA. In-vivo nude mice model indicated the anti-angiogenic potential of these acrylamides. This study has indicated the potential of 3-{4-[2-(1-Ethyl-2-methyl-1H-indol-3-yl)-ethyl-N-tert-butoxycarbonylsulfamoyl]-phenyl}-N-hydroxy-acrylamide (11, mean GI50 = 0.04 μM) as a lead molecule for further development as anti-cancer agent.
Export Options
About this article
Cite this article as:
Mehndiratta Samir, Pan Shiow-Lin, Kumar Sunil and Liou Jing-Ping, Indole-3-ethylsulfamoylphenylacrylamides with Potent Anti-proliferative and Anti-angiogenic Activities, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (7) . https://dx.doi.org/10.2174/1871520615666151013125221
DOI https://dx.doi.org/10.2174/1871520615666151013125221 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Label-Free Cell Phenotypic Assays for Assessing Drug Polypharmacology
Current Pharmaceutical Design Molecular Pathways of Interferon-Stimulated Gene 15: Implications in Cancer
Current Protein & Peptide Science Prospects and Limitations of T Cell Receptor Gene Therapy
Current Gene Therapy Is Biotechnological Next-Generation Therapeutics Promising Enough in Clinical Development to Treat Advanced Colon Cancer?
Current Pharmaceutical Biotechnology An Augmented Passive Immune Therapy to Treat Fulminant Bacterial Infections
Recent Patents on Anti-Infective Drug Discovery Tools For Decision-Making In Older Cancer Patients. Role Of The Comprehensive Geriatric Assessment
Anti-Cancer Agents in Medicinal Chemistry Personalized Medicine in Oncology: A Personal View with Myths and Facts
Current Clinical Pharmacology Novel Strategies and Model Studies for Colon Targeted Drug Delivery
Drug Delivery Letters Chronic Inflammation and Colorectal Cancer: The Role of Vascular Endothelial Growth Factor
Current Pharmaceutical Design Natural Compounds as Antagonists of Canonical Wnt/β-Catenin Signaling
Current Chemical Biology The Osteopontin Tissue Level as a Breast Cancer Biomarker in Females After Mastectomy Measured by the Capillary Gel Electrophoresis Technique
Combinatorial Chemistry & High Throughput Screening Efficacy and Safety of Bevacizumab in Glioblastomas
Current Medicinal Chemistry Immune Mechanism, Aging, Season and Diseases: Modulatory Role of Melatonin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Gut Inflammation: Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities
Current Pharmaceutical Design Unveiling the Transient Protein-Protein Interactions that Regulate the Activity of Human Lemur Tyrosine Kinase-3 (LMTK3) Domain by Cyclin Dependent Kinase 5 (CDK5) in Breast Cancer: An in silico Study
Current Proteomics miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Means to an End of Tumor Cell Resistance to Chemotherapeutic Drugs Targeting Thymidylate Synthase: Shoot the Messenger
Current Drug Targets Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry